antibodies
The expansion is one of several updates on the DNA synthesis firm's plans for its fiscal year 2022, which began last month.
Twist Bioscience Reports 17 Percent Growth of Fiscal Q4 Revenues, to Acquire Abveris
The firm has entered into a definitive agreement to acquire Abveris, an antibody discovery company, for up to $190 million in stock and cash.
Twist Bioscience, DeepCDR Collaborate on Antibody Library Design
Basel, Switzerland-based DeepCDR combines deep learning computational methods with a proprietary mammalian display antibody platform.
Twist Bioscience, Adicet Bio Ink Cancer Collaboration; Barclays Initiates Twist Coverage
Twist will provide its single-chain variable fragment and single-domain VHH antibody (nanobody) technologies to discover unique target-specific binders.
Twist Bioscience, SomaLogic Partner on Antibodies, Target Discovery
Twist will use any antibodies discovered under the program for its internal pipeline, with the potential to license the most promising ones to a development partner.
May 12, 2021
Mar 31, 2021
Feb 26, 2021
Aug 6, 2020
Twist Bioscience Q3 Revenues Grow 56 Percent
Jun 4, 2020
Twist Bioscience Prices $100M Stock Offering
May 12, 2020
Adaptive Biotechnologies Q1 Revenues Grow 65 Percent
May 12, 2020